Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program

Core Viewpoint - Inspire Medical Systems, Inc. has authorized a share repurchase program of up to $200 million to return capital to stockholders while continuing to invest in growth opportunities, particularly the launch of its next-generation neurostimulation system, Inspire V [1][2]. Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA) [3]. - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3]. Financial Strategy - The share repurchase program is based on the company's historical and expected business performance, cash and liquidity position, and market conditions [2]. - The program allows for flexibility in the timing, manner, price, and amount of repurchases, which may occur through various transaction methods [2]. - The share repurchase program is set to expire on August 7, 2027, unless terminated or extended by the Board [2]. Product Launch - Inspire V represents the largest product launch in the company's history, with significant investments in marketing and expansion to support this initiative [2]. - The company expresses confidence in its growth prospects due to low market penetration and believes its stock is undervalued [2].